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Justus T. Strauch, MD, Ulrich F. W. Franke, MD, Martin Breuer, MD, Jens Wippermann, MD, Thorsten Wittwer, MD,
Navid Madershahian, MD, Mirko Kaluza, and Thorsten Wahlers, MD, Jena, GermanyThe Impella Recover 100 (Impella CardioSystems AG,Aachen, Germany) is an intravascular microaxial bloodpump intended to provide short-term mechanical sup-port for acutely reduced left ventricular function in the
setting of postcardiotomy heart failure refractory to high-dose
inotropic support and intra-aortic balloon pump support. The low-
cost device is fast to insert across the aortic valve through a 10-mm
vascular graft sewn to the ascending aorta, avoiding the use of
cardiopulmonary bypass, is simple to remove, and is associated
with good properties for weaning.1-3 However, the Impella has just
recently been introduced into clinical practice, and no information
is available about its use in patients who have previously under-
gone biologic aortic valve replacement, especially with small
prosthesis sizes.
This report summarizes our initial clinical experience with such
a patient. It should encourage the surgical community to take the
device into consideration for borderline indications as a last resort.
Clinical Summary
A 69-year-old woman was admitted to our hospital after a diag-
nosis of coronary artery disease and severe aortic valve stenosis.
The patient’s history showed myocardial infarction of the anterior
wall weeks previously, with multiple coronary artery interventions
to the left anterior descending coronary artery, including stent
implantation. In addition, aortic valve stenosis was diagnosed, with
a peak-to-peak gradient of 61 mm Hg, an effective valve orifice
area of 0.64 cm2, and left ventricular end-diastolic pressure of 30
mm Hg. Left ventricular ejection fraction was 25%, and Euro-
SCORE at the time of the operation was 12.
The patient underwent technically uneventful coronary artery
revascularization with thoracic artery grafting to the left anterior
descending coronary artery and aortic valve replacement with a 21
mm sized stented biological prosthesis. Weaning from cardiopul-
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The Journal of Thoracicmonary bypass was accomplished with moderate catecholamine
support. Shortly after coming off cardiopulmonary bypass, the
patient had low cardiac output syndrome with an increase in left
atrial pressure, decline of cardiac output, and an increased need for
inotropic support. Subsequently, the patient underwent implanta-
tion of an intra-aortic balloon pump to control postcardiotomy
failure. The patient’s clinical condition deteriorated further,
with a rise in inotropic support (epinephrine at 0.39 g/
[kg · min] and norepinephrine of 1.1 g/[kg · min]). We there-
fore considered further left ventricular support; however, we
hesitated to insert an Impella left ventricular assist device
because with a 21-mm stented biologic valve it is said to be
impractical to get through the biologic stented valve prosthesis.
The pump body in its current existing form shows 7.3-mm
diameter at the level of the outflow area located directly above
the aortic valve area, and surgeons are commonly afraid of
injuring the leaflet tissue of the valve.
After further impairment in the patient’s condition, we decided
to implant the Impella as final supportive therapy, after balancing
all the pros and cons. After rethoracotomy, a 10-mm vascular graft
was sewn to the ascending aorta (Figure 1). Without cardiopulmo-
nary bypass, the device was inserted in a retrograde fashion across
the stented aortic bioprosthesis from the ascending aorta into the
cavity of the left ventricle. There were no technical difficulties
regarding the previously described small orifice area of the 21-mm
stented bioprosthesis for the device insertion. Under transesopha-
geal echocardiographic guidance, only one attempt was necessary
to get the device through the prosthesis (Figure 2). During the
surgical procedure, transesophageal echocardiography played an
essential role in the anatomic evaluation of the heart and correct
intraventricular positioning of the device,4 as did the careful ob-
servation of the pressure-differential curve on the device control.
Device implantation resulted in a flow of 4.9 L/min, and the
patient’s condition stabilized throughout the next 24 hours, with a
decline in catecholamine support. The patient died 4 days later
with signs of multiorgan failure resistant to therapy, dominated by
liver failure with a missing neogenesis of glucose and a loss of
coagulation.
Discussion
We encourage cardiac surgeons in the situation of critically ill
patients in the setting of postcardiotomy heart failure, even after
stented biologic aortic valve prosthesis implantation, to take the
Impella Recover 100 device into consideration. We advise sur-
geons to embrace the use of this device as soon as possible for
special borderline indications and not to waste any time in partic-
ularly life-threatening situations.
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